ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Apr 18, 2023 12:00 JST
Source:
Avance Clinical
Avance Clinical CEO Joins Global BioPharma Panel for Evolution Europe Summit 2023
ADELAIDE, AUS & SAN DIEGO, Apr 18, 2023 - (ACN Newswire) - Avance Clinical the leading award-winning Australian and North American biotech CRO that offers a GlobalReady program to early phase biotech companies to speed up the path to regulatory approval, has been invited to join the Evolution Europe Summit 2023 (Montreux, Switzerland 20 April - 21 April 2023). The panel discussion is focused on the evolution of clinical trials including technology, DCTs, reducing time and cost, drug development planning for approvals, and scaling globally in later phases.
Avance Clinical CEO, Yvonne Lungershausen has been invited to share the Australian and US CRO experience and future projections with a focus on patient centricity and Decentralized Clinical Trials (DCTs) at the Evolution Europe Summit 2023.
Avance Clinical was recently identified by GlobalData as a global leader in DCT technology.
The Evolution Summit is an invitation-only, premium forum bringing leading clinical research executives and innovative solution providers. The summit's content is aligned with key clinical R&D challenges and interests, relevant market developments, and practical and progressive ideas and strategies adopted by successful pioneers. See full details here.
https://www.april23.evolution-summit.com/
Avance Clinical has recently been ranked as the world leader in DCT technology adoption by GlobalData and Clinical Trial Arena in the CRO sector. The report found 46% of Avance Clinical's trials incorporated some elements of DCT technologies in 2022 including telemedicine, remote monitoring, and digital data collection.
The DCT report also noted that Avance Clinical's staff training in the latest technologies was a key factor in the ranking. See the full report here.
https://www.clinicaltrialsarena.com/features/year-in-review-dct-2022/
Avance Clinical's unique clinical offering GlobalReady enables biotechs that have completed early to mid-phases in Australia to rapidly and seamlessly transition to the US in preparation for FDA approvals, all with the one CRO and dedicated teams across both regions, which reduces time and cost and delivers quality data.
There are currently more than 280 Phase III global trials that have conducted their Phase I study in Australia, which demonstrates Australian data acceptability with the FDA and other major regulatory authorities.
More than 40 biotech clients are now taking advantage of Avance Clinical's GlobalReady program.
This seamless GlobalReady journey is designed so biotechs can:
- Take advantage of the Australian early-phase clinical trial landscape (No IND and 43.5% tax rebate)
- Transition or expand into North America for later phases - without changing CROs (retain study knowledge and processes/team)
- Seamlessly operationalize global dose-escalation and dose-expansion trials across the two regions
- Harness significant speed and cost advantages
- Be assured of quality data - transferable and readily acceptable by the FDA and other regulatory authorities
Find out more:
- Learn about the Australian Advantage here.
https://www.avancecro.com/the-australian-advantage/
- Learn about the GlobalReady model here.
https://www.avancecro.com/avance-clinical-north-america-operations/
- For more information about the benefits of running your next study with Avance Clinical contact us:
enquiries@avancecro.com
About Avance Clinical
Avance Clinical is the largest premium full-service Australian and US CRO delivering quality clinical trials, with globally accepted data, in Australia, New Zealand and the US for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services. www.avancecro.com
Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past three years, has been providing CRO services in the region for more than 24 years.
Pre-clinical through to Phase 1 and 2
Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 110 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.
Technology
Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, IBM Watson and Medrio are just some of the technology partners.
Media Contact:
Avance Clinical
Kate Thompson
media@avancecro.com
Source: Avance Clinical
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Fujitsu Kozuchi AI technologies assist AKOS AI in delivering solutions for EU AI compliance
Apr 18, 2025 17:41 JST
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
Apr 18, 2025 16:52 JST
Hitachi Industrial Equipment Systems Launches Next-Generation Inverter System to Support Stable, Resilient Power Grids
Apr 18, 2025 16:46 JST
MHIEC Receives Order from the Bureau of Sewerage of the Tokyo Metropolitan Government for Rebuilding of Sewage Sludge Incineration Facility
Apr 17, 2025 14:44 JST
Fujitsu collaboration with Supermicro and Nidec to reduce data center energy consumption
Apr 17, 2025 10:32 JST
Fujitsu's Japanese language enhanced LLM Takane offering now available on Nutanix Enterprise AI solution
Apr 16, 2025 11:24 JST
Isuzu and Fujitsu sign partnership agreement to commercialize software defined vehicles
Apr 15, 2025 12:29 JST
MHI Awarded a Study on CO2 Capture Modules for FPSOs
Apr 15, 2025 10:46 JST
Mitsubishi Motors Begins Shipping Xforce HEV Model in Thailand
Apr 11, 2025 15:03 JST
Collaboration to Make Engine-Equipped Vehicles Carbon Neutral Using Synthetic Fuel
Apr 11, 2025 14:03 JST
TGR to Launch Evolved GR Yaris
Apr 11, 2025 13:35 JST
Fujitsu develops employee training platform for Seven-Eleven Japan to accelerate store digitalization
Apr 11, 2025 11:29 JST
Mitsubishi Corporation makes DennoKotsu an equity-method affiliate company, strengthening efforts to address regional transportation challenges
Apr 11, 2025 10:39 JST
JCB Enhances Customer Experience with Expanded Payment Acceptance for App Store and Apple Services in Asia
Apr 11, 2025 10:00 JST
Fujitsu and Headwaters trial on-device generative AI solution to streamline JAL cabin crew workflows
Apr 11, 2025 09:07 JST
Mitsubishi Logisnext Delivers Container Terminal Gate System with Enhanced Functionality to Port of Osaka
Apr 10, 2025 16:23 JST
Mitsubishi Shipbuilding Acquired Approval in Principle (AiP) from Classification Society for the Basic Design of an Onboard Carbon Capture and Storage System
Apr 10, 2025 14:17 JST
Honda NC750X Named Winner in 2025 Red Dot Design Award: Product Design Category, EM1 e: Wins 2025 iF Design Award: Product Design Category
Apr 10, 2025 13:13 JST
Mitsubishi Corporation to Participate in Demonstration Project for New Hydrogen-Based Ironmaking
Apr 09, 2025 18:22 JST
SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis
Apr 09, 2025 15:49 JST
More Latest Release >>
Related Release
Avance Clinical Appoints Asia Regional Director as Part of Global Expansion Program
July 23 2024 16:00 JST
New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs
June 04 2024 22:00 JST
Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical
May 31 2024 16:00 JST
Avance Clinical Expands Further into APAC with New Clinical Operations in South Korea
May 08 2024 09:00 JST
Avance Clinical Showcases Clinical Excellence at World Orphan Drug Conference in Boston, April 23-25
April 19 2024 16:00 JST
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 Study
March 28 2024 14:42 JST
Avance Clinical CEO Talks with SCRIP about US Biotech Sector "Green Shoots" and a New CRO Report
February 28 2024 08:00 JST
Latest Analysis Reveals 65% of US Biotechs Struggle to Identify Suitable CRO Partner
January 12 2024 16:00 JST
Avance Clinical Invited to Brief 45 Korean Biotechs on Their GlobalReady Drug Development Pathway from Korea and Australia to the US
October 19 2023 09:00 JST
Avance Clinical at ASCO & BIO 2023: Early Phase Oncology Trials Increasingly Elaborate and Demand More Patients
May 30 2023 10:00 JST
More Press release >>